Use of Fc-MBL to Detect and Monitor the Presence of PAMPs During Septic Shock

NCT ID: NCT03457038

Last Updated: 2019-04-18

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-10-18
• Study Completion Date: 2019-07-18

Brief Summary

Use Mannose Binding Lectin (MBL) as a biomarker to measure levels of Pathogen- Associated Molecular Patterns (PAMP) during septic shock. This will allow evaluating interest of this biomarker to monitor and manage a septic shock. Consecutive patients admitted for sepsis in Intensive Care Unit Department will be included. This biomarker will be compared to all the parameters monitored usually for these patients in standard care.

Detailed Description

Septic shock still represent a major cause of admission in intensive care unit, incidence of severe sepsis is increasing, even in western countries, due to aging populations and comorbidities. Definition of septic shock was revised in 2016 by a task force, which emphasizes the need for future iterations. Indeed, there are no simple clinical or biological criteria ton diagnose septic patients with high risk of shock, or to prognose its severity. C-reactive protein (CRP) and procalcitonin (PCT) are the wider biomarkers used to monitor septic patients. But they do not correlate with sepsis severity and moreover do not distinguish unequivocally between infection and noninfected systemic inflammatory response syndrome (SIRS). Each microorganism has number of PAMPs, cell wall components (lipopolysaccharide endotoxin, peptidoglycan, outer membrane vesicles), flagella, mannan… High levels of these pathogen fragments are released in the bloodstream during sepsis. They trigger release of inflammatory cytokines that drive the sepsis cascade. Mannose binding lectin plays a pivotal role in innate immunity, binding with surface sugars of wide range of pathogens and their fragments. Thus MBL promotes opsonophagocytosis and activates the lectin-complement pathway. Fc-MBL, an engineered version of MBL has been developed to capture microorganism and treat sepsis. An ELISA, using Fc-MBL was developed to measure PAMPs in whole blood during sepsis. This assay will use Fc-MBL ELISA to quantify PAMPs during septic shock, to improve diagnostic and monitoring. But also, identifying patients with high levels of PAMPs for dialysis-like sepsis therapies.

PAMP's level will be compared to clinical, biological, microbiological and therapeutic outcomes. Its sensitivity will be evaluated by its kinetic among a septic shock (defined with Sepsis-3 criteria) and by correlation with CRP (C-Reactive Protein) and PCT (Procalcitonin). Its specificity will be evaluated by comparing its levels during septic and non-septic shocks.

Conditions

Septic Shock

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Patient with Septic Shock

Patient Hospitalized in Intensive Care Unit for sepsis of any etiology. The number of follow-up visits will not be changed compared to usual patient follow-up hospitalized in the intensive care unit but there will be blood testing more frequently

Group Type: EXPERIMENTAL

Blood Test

Intervention Type: BIOLOGICAL

Addition to the current care but during the normal follow-up visit :

• At the entrance to the service: search for bacterial 16S RNA in the blood
• Additional blood tests (4) at T6-12-18 and 36h
• At each visit: Sampling of an additional heparinized blood tube for the assay PAMPs.
• 1 time per day: Assay of CRP and PCT from samples taken in common practice
• J30: Assessment of the vital status of the patient

Interventions

Blood Test

Addition to the current care but during the normal follow-up visit :

• At the entrance to the service: search for bacterial 16S RNA in the blood
• Additional blood tests (4) at T6-12-18 and 36h
• At each visit: Sampling of an additional heparinized blood tube for the assay PAMPs.
• 1 time per day: Assay of CRP and PCT from samples taken in common practice
• J30: Assessment of the vital status of the patient

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Adult patients
• Hospitalized in Intensive Care Unit for sepsis of any etiology
• Patients with shock criteria: defined by a hypotension, hyperlactatemia, the use of vasopressive drugs.
• Patient affiliated to a social security scheme- Patient giving consent

Exclusion Criteria

• Minor patients
• Organ transplant
• Immunosuppressive drugs, other than corticosteroids
• Patients who decline participating to the assay
• Persons placed under legal protection, guardianship
• Pregnant woman
• Subject participating in another search including a exclusion period still in progress at pre-inclusion

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Harvard Medical School (HMS and HSDM)

OTHER

Sponsor Role: collaborator

University Hospital, Toulouse

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Eric Oswald, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Toulouse

Locations

University Hospital Toulouse

Toulouse, , France

Site Status: RECRUITING

Countries

France

Central Contacts

Eric Oswald, MD

Role: CONTACT

oswald.e@chu-toulouse.fr

5 67 69 04 17 ext. 33

Isabelle OLIVIER, PhD

Role: CONTACT

olivier.i@chu-toulouse.fr

5 61 77 70 51 ext. 33

Facility Contacts

Eric Oswald, MD

Role: primary

oswald.e@chu-toulouse.fr

5 67 69 04 17 ext. 33

Isabelle Olivier, PhD

Role: backup

olivier.i@chu-toulouse.fr

5 61 77 70 51 ext. 33

Other Identifiers

2017-A01686-47

Identifier Type: OTHER

Identifier Source: secondary_id

RC31/17/0157

Identifier Type: -

Identifier Source: org_study_id